# **1** Supplemental Material:

#### 2

**Content:** 2. Materials and methods SM-1 Table S1. Mobile phase compositions for the two separation methods.3 SM-2 Table S2. Optimized MS/MS parameters for the eight PhACs. SM-3 Table S3. Acute and chronic toxicity data of the PhACs on algae, daphnids and fish. SM-4 Table S4. Aquatic toxicity data for the five detected PhACs and the most sensitive SM-5 aquatic species. 3 4 5 6 7 8 9 10 11 12 13 14 15 16

17

#### 18 2. Materials and methods

19

## 20 2.1. Materials and fish exposure

Eight PhACs were selected for this study based on their high usage rates and 21 frequent occurrence in surface water in China.<sup>1,2</sup> The standards of roxithromycin 22 (ROX), erythromycin (ERY), ketoconazole (KCZ), ibuprofen (IBU), diclofenac (DIC), 23 propranolol (PRO), carbamazepine (CBZ) and  $17\alpha$ -ethinylestradiol (EE2) were 24 purchased from the laboratory of Dr. Ehrenstorfer (Augsburg, Germany). 25 Erythromycin-13C,d3, carbamazepine-d10, ibuprofen-d3 and estrone-d4 were 26 obtained from Sigma-Aldrich (Flanders, New Jersey, USA). Crucian carp were 27 purchased from the Nanjing Institute of Fishery Science (Nanjing, China). 28

29 Crucian carp (Carassius auratus) is an important economic species widely distributed in the freshwaters of China. It has been demonstrated to be a very sensitive 30 species to study the toxic effects of pollutants on aquatic organisms.<sup>3</sup> In the laboratory, 31 the fish were fed every day with commercial fish food (6% of body weight/day). 32 According to OECD guideline 305,<sup>4</sup> the exposure water's quality was checked daily 33 and maintained at conditions suitable for crucian carp (Water temperatures  $9 \pm 1$  °C; 34 pH 7.4  $\pm$  0.3; DO 7.5  $\pm$  0.5 and CaCO<sub>3</sub> 110.5  $\pm$  3.5 mg L<sup>-1</sup> ). Feces and uneaten food 35 were removed every day by suction. Natural light conditions were used throughout 36 the experiment. 37

38

#### 39 2.2. Biomarker assays, HSI, EROD and GST

Hepatosomatic index (HSI) was calculated as follow:  $HSI = (W_L/W_B) \times 100$ , where  $W_L$  is the weight of the liver in grams and  $W_B$  is the body weight in grams. Liver samples were homogenized in nine volumes of cold buffer (0.15 M KCl, 0.1 M Tris–HCl, pH 7.4) and centrifuged for 25 min (10,000×g) at 4 °C. The supernatants were used as the extract for enzymatic activity determination. The use of S9 fractions is convenient and relatively cheap compared with using cytosol and microsomes. The

EROD activity was determined at 572 nm using a microplate reader. Specifically, 10 46 µL of supernatant, 140 µL buffer (0.1 M Tris, 0.15 M KCl, pH 8.0) and 10 µL of 2 47 µM 7-ethoxyresorufin were added to a 96-well microplate. The reaction was then 48 initiated at 25 °C for 30 min by adding 40 µL of 2.1 mg mL<sup>-1</sup> NADPH. NADPH was 49 replaced by H<sub>2</sub>O in the control wells. The molar extinction coefficient of the resorufin 50 was 73 L mmol<sup>-1</sup> cm<sup>-1</sup>. The EROD activity was expressed as pmol mg pro<sup>-1</sup> min<sup>-1</sup>. 51 GST activity was determined at 340 nm by adapting to a microplate reader, using 30 52  $\mu$ L of homogenate and 150  $\mu$ L of the reaction solution (100  $\mu$ L of 0.1 mM potassium 53 phosphate, 10 µL of 1.0 mM 1-chloro-2,4-dinitrobenzene, 10 µL of 1.0 mM GSH and 54 880 µL H<sub>2</sub>O) in microplates, and this activity was measured for 3 min. GST activity 55 was expressed as nmol mg  $pro^{-1} min^{-1}$ . 56

57

#### 58 2.3. Sample extraction

Tissue samples were extracted by pressurized liquid extraction (PLE) using a 59 Dionex ASE 350 system (Thermo Fisher, Germering, Germany). Each tissue sample 60 (1 g wet weight (ww) for muscle, gill and brain and 0.5 g ww for liver) was 61 thoroughly mixed with hydromatrix and the mixture was put into a 22-mL stainless 62 steel extraction cell containing a glass-fiber filter (27-mm diameter, type D28, Dionex) 63 in the cell inlet and outlet. The extracting solvent was 100% methanol, and the 64 operating conditions were as follows: extraction temperature, 70 °C; extraction 65 pressure, 1500 psi; preheating period, 5 min; static extraction, 5 min; nitrogen purge, 66 180 s; and three static cycles. 67

Each PLE extract was concentrated to approximately 1 mL in a Büchi R200 68 (Labortechnik, Flawail, Switzerland) rotary evaporator set at 45 °C and 19600 Pa in a 69 50-mL round-bottomed flask. Then, the extract was transferred to a 15-mL conical 70 tube and the round-bottomed flask was rinsed twice with 0.5 mL of methanol and 71 evaporated to dryness using a multi-sample N-EVAP with a nitrogen stream and 72 water bath at 50 °C. After solvent evaporation the extract was redissolved in 1 mL of 73 acetonitrile, which has a low solubility for lipids. A freezing-lipid technique was 74 applied, by means of redissolving the extract in acetonitrile and storing the extract in 75 the freezer at -80 °C for 4 h. Most of the lipids precipitated out of solution and the 76 extract was immediately centrifuged at 0 °C and 12000×g for 15 min. The 77 supernatants were decanted into a chromatography bottle and reconstituted with 1 mL 78 of acetonitrile, and 50  $\mu$ L of the 1 mg L<sup>-1</sup> mixture containing the internal standards 79 were added. 80

Water samples (500 mL) were passed through Oasis HLB 6cc SPE cartridges (500 mg, Waters, USA). The cartridges were preconditioned with 6 mL of methanol and 6 mL of water. The samples were eluted from the cartridges using 2 × 3 mL of methanol. The extracts were evaporated to dryness under a stream of nitrogen, reconstituted with 1 mL acetonitrile, and analyzed by UPLC/MS/MS.

86

## 87 2.4. Instrumental analysis

Liquid chromatography was performed on an Agilent 1290 ultra-high performance liquid chromatography (UPLC) system (Agilent Technologies) consisting of a binary pump, a micro-vacuum degasser, an autosampler equipped with

a 1200 bar injection valve and a column oven (set to 30 °C). Analytes were separated 91 on an Eclipse Plus C18 (150 mm × 4.6 mm, 5 µm, Agilent Technologies) column 92 preceded by a C18 guard column at a flow rate of 0.3 mL min<sup>-1</sup>. The injection volume 93 was 5  $\mu$ L. A binary gradient consisting of 0.1% (v/v) formic acid/0.02 mM 94 ammonium acetate in water and 100% acetonitrile was employed to achieve 95 separation as shown in Table S1. Detection was performed with an Agilent 6460 triple 96 quadrupole mass spectrometer equipped with an electrospray ionization source (ESI). 97 The ROX, ERY, KCZ, PRO and CBZ in the tissue and water samples were analyzed 98 in the positive mode, whereas the DIC, IBU and EE2 were analyzed in the negative 99 mode. The capillary voltage was held at 4 KV and the gas flow was set at 6 L min<sup>-1</sup>. 100 The pressure of the nebulizing gas was 35 psi. The sheath gas temperature was held at 101 350 °C and the gas flow was 9 L min<sup>-1</sup>. The triple quadrupole was used in the 102 multiple-reaction monitoring (MRM) mode to identify and quantify the compounds. 103 The collision energy, the fragmentor voltage, the precursor and the production ions 104 optimized by the direct infusion of standard compounds are presented in Table S2. 105

Whole analytical procedures were monitored using strict quality assurance and control measures. The method sensitivity was calculated by determining the method detection limits (MDL), the limit of detection (LOD) and the limit of quantitation (LOQ) for the target compounds. The MDLs of the target compounds calculated using standard solutions were 0.05–0.12 ng L<sup>-1</sup>. For the water samples, the LODs and LOQs of the target compounds were 0.07–0.15 and 0.27–0.65 ng L<sup>-1</sup>, respectively. Similarly, the LODs and LOQs of the target compounds corresponding to fish tissues were 0.1–0.3 and 0.4–1.2 ng g<sup>-1</sup>, respectively. Satisfactory recoveries were obtained for the target compounds in the range of 83.7-105.2% for the water samples and 62.4-83.6% for the fish samples.

116

## 117 2.5. Environmental implications

An environmental risk assessment of individual pharmaceuticals was performed based on chronic data and acute data according to the EMA guideline and REACH guideline<sup>5</sup>, respectively. Typically, the risk quotient (RQ) of individual pharmaceuticals is calculated via their measured environmental concentration (MEC) divided by the predicted no-effect concentration (PNEC), as shown in Equation (1):

123 RQ = 
$$\frac{MEC}{PNEC}$$
 (1)

According to the REACH guidance document, to estimate a PNEC on the basis of 124 toxicity data, when only the short-term/acute toxicity data EC50 or LC50 are 125 available, the calculation of PNEC is obtained from the EC50 or LC50 divided by an 126 assessment factor (AF) of 1000. Once the long-term/chronic NOEC values for one, 127 two or three trophic levels are available, an AF of 100, 50 or 10 is used.<sup>5</sup> In this study, 128 an AF of 1000, 100 or 10 was used in relation to the toxicity of PhACs. In this study, 129 the acute or chronic toxicity data of the detected PhACs on non-target organisms were 130 collected from the literature and are shown in Table S3. 131

The environmental risk assessment of pharmaceutical mixtures was evaluated by the approach recently proposed by Backhaus and Faust. The approach for calculating the mixture RQ is outlined by Equation (2): the calculation of  $\Sigma RQ_{MEC/PNEC}$ , based on 135 the sum of MEC/PNEC values. The toxicity data EC50, LC50 or NOEC are136 represented by EC50 in Equations (2).

137 
$$\Sigma RQ_{MEC/PNEC} = \sum_{i=1}^{n} \frac{MEC_{i}}{PNEC_{i}}$$

$$= \sum_{i=1}^{n} \frac{MEC_{i}}{\min(EC50_{aglse}, EC50_{daphnids}, EC50_{fish})_{i} \times (1/AF_{i})}$$
139 (2)

140 The biomarker response data for each point were standardized according to141 Eq.(3):

142 
$$Y_i = (X_{i-m})/s$$
 (3)

143 where  $Y_i$  is the standardized value of the biomarker,  $X_i$  is the mean value of a 144 biomarker at each point, and *m* and *s* are the mean value and the standard deviation of 145 a biomarker with all of the sampling points considered, respectively.

Using standardized data, Zi was then calculated as Zi = Yi or Zi = -Yi in the case of a biomarker responding to contamination by induction or inhibition, respectively. The minimum value (minZi) for each biomarker at all of the points was calculated from the standardized response value. The score of each biomarker response (*Si*) was calculated as:

$$151 \quad \mathrm{Si} = \mathrm{Zi} + |\mathrm{minZi}| \tag{4}$$

Finally, to obtain an integrated multi-biomarker response, the EIBR value was calculated as the sum of the weighting of the biomarker and the biomarker score as follows:





| Time (min)    | Composition of the mobile phase (%)  |                          |
|---------------|--------------------------------------|--------------------------|
| Positive mode | Eluent A1 (0.1% (v/v) Formic acid)   | Eluent B1 (Acetonitrile) |
| 0             | 80                                   | 20                       |
| 0.5           | 80                                   | 20                       |
| 4             | 10                                   | 90                       |
| 5             | 10                                   | 90                       |
| 5.5           | 80                                   | 20                       |
| Negative mode | Eluent A2 (0.02 Mm Ammonium acetate) | Eluent B2 (Acetonitrile) |
| 0             | 80                                   | 20                       |
| 0.5           | 80                                   | 20                       |
| 6             | 5                                    | 95                       |
| 6.5           | 80                                   | 20                       |

## 

#### 

#### 163 Table S2.

| Compound | Precursor ion (a) | Product ion<br>(a) | Fragmentor<br>voltage (v) | Collision energy<br>(v) | polarity |
|----------|-------------------|--------------------|---------------------------|-------------------------|----------|
| ROX      | 837               | 679.6              | 140                       | 10                      | Positive |
| ERY      | 734.2             | 576.4              | 140                       | 20                      | Positive |
| KCZ      | 531.3             | 489.3              | 140                       | 5                       | Positive |
| PRO      | 260.2             | 116.2              | 120                       | 20                      | Positive |
| CBZ      | 237.2             | 194.2              | 140                       | 20                      | Positive |
| EE2      | 295               | 145                | 160                       | 44                      | Negative |
| DIC      | 294.2             | 250                | 80                        | 6                       | Negative |
| IBU      | 205               | 161                | 60                        | 0                       | Negative |

| 164 |  |
|-----|--|
| 165 |  |
| 166 |  |
| 167 |  |
| 168 |  |
| 169 |  |

170 Table S3.

| Compound | Non-target          | Toxicity data | Endpoint       | Toxicity | AF   | PNEC          | Reference |
|----------|---------------------|---------------|----------------|----------|------|---------------|-----------|
|          | organism            | $(mg L^{-1})$ |                |          |      | $(ng L^{-1})$ |           |
| ROX      | Pseudokirchneriella | NOEC = 0.01   | Growth         | Chronic  | 100  | 100           | 6         |
|          | subcapitata         |               |                |          |      |               |           |
|          | Selenastrum         | EC50 = 4.0    | Growth         | Acute    | 1000 | 4000          | 7         |
|          | capricornutum       |               |                |          |      |               |           |
|          | Daphnia magna       | EC50 = 7.1    | Immobilization | Acute    | 1000 | 7100          | 8         |
|          | Oryzias latipes     | LC50 = 288.3  | Mortality      | Acute    | 1000 | 288300        | 8         |
| ERY      | Pseudokirchneriella | EC50 = 0.02   | Growth         | Chronic  | 1000 | 20            | 9         |
|          | subcapitata         |               |                |          |      |               |           |
|          | Selenastrum         | EC50 = 0.037  | Growth         | Acute    | 1000 | 37            | 10        |
|          | capricornutum       |               |                |          |      |               |           |
|          | Ceriodaphnia dubia  | EC50 = 0.22   | Growth         | Chronic  | 1000 | 220           | 9         |
|          | Ceriodaphnia dubia  | EC50 = 10.23  | Immobilization | Acute    | 1000 | 10230         | 9         |
|          | Oryzias latipes     | NOEC = 100    | Growth         | Chronic  | 100  | 1000000       | 11        |
|          | Oryzias latipes     | LC50 > 100    | Mortality      | Acute    | 1000 | 100000        | 12        |
| DIC      | Pseudokirchneriella | NOEC > 10     | Growth         | Chronic  | 100  | 100000        | 13        |
|          | subcapitata         |               |                |          |      |               |           |
|          | Pseudokirchneriella | EC50 = 16.3   | Mobility       | Acute    | 1000 | 16300         | 14        |
|          | subcapitata         |               |                |          |      |               |           |
|          | Ceriodaphnia dubia  | NOEC = 1      | Reproduction   | Chronic  | 100  | 10000         | 13        |
|          | Daphnia magna       | EC50 = 22.43  | Immobilization | Acute    | 1000 | 22430         | 14        |
|          | Oncorhynchus mykiss | NOEC = 0.001  | Cytotoxicity   | Chronic  | 100  | 10            | 15        |
|          | Oncorhynchus mykiss | LC50 = 5.6    | Cytotoxicity   | Acute    | 1000 | 5600          | 16        |
| PRO      | Cyclotella          | NOEC = 0.094  | Growth         | Chronic  | 100  | 940           | 14        |
|          | meneghiniana        |               |                |          |      |               |           |
|          | Cyclotella          | EC50 = 0.244  | Growth         | Acute    | 1000 | 244           | 14        |
|          | meneghiniana        |               |                |          |      |               |           |

|     | Ceriodaphnia dubia | NOEC = 0.009  | cytotoxicity       | Chronic | 100  | 90     | 17 |
|-----|--------------------|---------------|--------------------|---------|------|--------|----|
|     | Ceriodaphnia dubia | LC50 = 0.8    | Reproduction       | Acute   | 1000 | 800    | 18 |
|     | Oryzias latipes    | NOEC = 0.0005 | Reproduction       | Chronic | 10   | 50     | 18 |
|     | Oryzias latipes    | LC50 = 11.4   | Mortality          | Acute   | 1000 | 11400  | 12 |
| CBZ | Desmodesmus        | EC50 = 74.0   | Growth             | Chronic | 1000 | 74000  | 17 |
|     | subspicatus        |               |                    |         |      |        |    |
|     | Cyclotella         | EC50 = 31.6   | Growth             | Acute   | 1000 | 31600  | 14 |
|     | meneghiniana       |               |                    |         |      |        |    |
|     | Ceriodaphnia dubia | NOEC = 0.025  | Reproduction       | Chronic | 100  | 250    | 13 |
|     | Daphnia magna      | EC50 = 13.8   | Mobility           | Acute   | 1000 | 13800  | 13 |
|     | Danio rerio        | NOEC = 25     | Embryos and larvae | Chronic | 100  | 250000 | 13 |
|     |                    |               | mortality          |         |      |        |    |
|     | Oryzias latipes    | LC50 = 45.87  | Mortality          | Acute   | 1000 | 45870  | 12 |

```
171
```

## 

## 173 Table S4.

|    | Compound | Non-target organism             | Toxicity data $(mg L^{-1})$ | Toxicity | AF   | PNEC<br>(ng L <sup>-1</sup> ) | Reference |
|----|----------|---------------------------------|-----------------------------|----------|------|-------------------------------|-----------|
| -  | ROX      | Pseudokirchneriella subcapitata | NOEC = 0.01                 | Chronic  | 100  | 100                           | 6         |
|    | ERY      | Pseudokirchneriella subcapitata | EC50 = 0.02                 | Chronic  | 1000 | 20                            | 9         |
|    | PRO      | Oryzias latipes                 | NOEC = 0.0005               | Chronic  | 10   | 50                            | 18        |
|    | CBZ      | Ceriodaphnia dubia              | NOEC = 0.025                | Chronic  | 100  | 250                           | 13        |
|    | DIC      | Oncorhynchus mykiss             | NOEC = 0.001                | Chronic  | 100  | 10                            | 15        |
| 17 | 4        |                                 |                             |          |      |                               |           |
| 17 | 5        |                                 |                             |          |      |                               |           |
| 17 | 6        |                                 |                             |          |      |                               |           |
| 17 | 7        |                                 |                             |          |      |                               |           |
| 17 | 8        |                                 |                             |          |      |                               |           |

181

- 182
- 183
- 184
- 185

```
186
```

- 187 **References**
- 1 Y. P. Duan, X. Z. Meng, Z. H. Wen, R. H. Ke, L. Chen, *Sci. Total Environ.*, 2013,
  447, 267-273.
- 190 2 G. Lu, X. Yang, Z. Li, H. Zhao, C. Wang, *Ecotoxicology*, 2013, 22, 50-59.
- 191 3 F. Chen, J. Gao, Q. Zhou, Environ. Pollut., 2012, 162, 91-97.
- 4 OECD guideline for testing of chemicals. No. 305, *bioaccumulation in fish: aqueous and dietary exposure*. Paris, 2012.
- 194 5 ECHA, Guidance on Information Requirements and Chemical Safety Assessment
- 195 Chapter R. 10: Characterisation of Dose [Concentration]-Response for
  196 Environment, 2008.
- 197 6 L. H. Yang, G. G. Ying, H. C. Su, J. L. Stauber, M. S. Adams, et al., Environ.
- 198 *Toxicol. Chem.*, 2008, 27, 1201-1208.
- 199 7 H. Sanderson, D. J. Johnson, C. J. Wilson, R. A. Brain, K. R. Solomon, Toxicol.
- 200 *Lett.*, 2003, 144, 383-395.
- 201 8 K. Choi, Y. Kim, J. Jung, M. H. Kim, C. S. Kim, N. H. Kim, et al., Environ. Toxicol.
- 202 *Chem.*, 2008, 27, 711-719.
- 9 M. Isidori, M. Lavorgna, A. Nardelli, L. Pascarella, A. Parrella, *Sci. Total Environ.*,
  2005, 346, 87-98.
- 205 10 K. Eguchi, H. Nagase, M. Ozawa, Y. S. Endoh, K. Goto, K. Hirata, et al., *Chemosphere*, 2004, 57, 1733-1738.
- 207 11 K. Ji, S. Kim, S. Han, J. Seo, S. Lee, Y. Park, et al., *Ecotoxicology*, 2012, 21,
  208 2031-2050.

- 209 12 J. W. Kim, H. Ishibashi, R. Yamauchi, N. Ichikawa, Y. Takao, M. Hirano, et al., *J. Toxicol. Sci.*, 2009, 34, 227-232.
- 211 13 B. T. Ferrari, N. Paxéus, R. L. Giudice, A. Pollio, J. Garric, *Ecotoxicol. Environ.* 212 Saf., 2003, 55, 359-370.
- 213 14 B. Ferrari, R. Mons, B. Vollat, B. Fraysse, N. Paxēaus, R. L. Giudice, et al.,
  214 *Environ. Toxicol. Chem.*, 2004, 23, 1344-1354.
- 215 15 J. Schwaiger, H. Ferling, U. Mallow, H. Wintermayr, R. D. Negele, *Aquat.*216 *Toxicol.*, 2004, 68, 141-150.
- 217 16 N. Laville, S. Ait-Aissa, E. Gomez, C. Casellas, J. Porcher, *Toxicology*, 2004, 196,
  218 41-55.
- 219 17 M. Crane, C. Watts, T. Boucard, Sci. Total Environ., 2006, 367, 23-41.
- 220 18 D. B. Huggett, B. W. Brooks, B. Peterson, C. M. Foran, D. Schlenk, Arch. Environ.
- 221 *Contam. Toxicol.*, 2002, 43, 229-235.